The Danish National Chronic Lymphocytic Leukemia Registry
- PMID: 27822100
- PMCID: PMC5094649
- DOI: 10.2147/CLEP.S99486
The Danish National Chronic Lymphocytic Leukemia Registry
Abstract
Aim: In 2008, the Danish National Chronic Lymphocytic Leukemia Registry was founded within the Danish National Hematology Database. The primary aim of the registry is to assure quality of diagnosis and care of patients with chronic lymphocytic leukemia (CLL) in Denmark. Secondarily, to evaluate adherence to national guidelines and to provide source data for research purposes.
Study population: All patients diagnosed with CLL in Denmark from 2008 onward are included in the registry. Patients are followed in one of nine hematology centers. All centers participate in the registry and are all obliged to collect data.
Main variables: Predefined data are collected at the time of diagnosis, and follow-up at the time of significant events: treatment, progression, transplantation, and death. Parameters included in the International Workshop on Chronic Lymphocytic Leukaemia criteria for diagnosis, and for decision on treatment initiation as well as characteristics included in the CLL International Prognostic Index are collected.
Descriptive data: To ensure full coverage of Danish CLL patients in the registry, both continuous queries in case of missing data, and cross-referencing with the Danish National Patient Registry are performed. Data from the registry are published in an annual report summarizing the collected data, the overall survival for yearly cohorts, and the degree of data coverage. Per year approximately 450 new patients with CLL are registered in the registry, cumulative as of July 1, 2015, 3,082 patients have been registered.
Conclusion: The Danish National CLL Registry is based within the Danish National Hematology Database. The registry covers a cohort of all patients diagnosed with CLL in Denmark since 2008. It forms the basis for quality assessment of CLL treatment in Denmark and offers a unique opportunity for population-based research.
Keywords: CLL; comorbidity; epidemiology; population based; survival; targeted treatment.
Conflict of interest statement
Carsten Utoft Niemann is a principal investigator in clinical trials sponsored by Roche (Basel, Switzerland), has received fees for consultancy from Roche, Janssen (NJ, USA), and Gilead (CA, USA), and has received research funding from the Danish Cancer Society. The authors report no other conflicts of interest in this work.
Figures


References
-
- The Danish Clinical Registries [homepage on the Internet] RKKP; Denmark: 2015. [Accessed March 7, 2016]. Available from: http://www.rkkp.dk/in-english/
-
- Danish Multidisciplinary Cancer Groups [homepage on the Internet] DMCG.DK; 2015. [Accessed March 7, 2016]. Available from: http://dmcg.dk/en.
-
- Oken MM, Creech RH, Tormey DC, et al. Toxicity and response criteria of the Eastern Cooperative Oncology Group. Am J Clin Oncol. 1982;5(6):649–655. - PubMed
-
- Hallek M, Cheson BD, Catovsky D, et al. Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: a report from the International Workshop on Chronic Lymphocytic Leukemia updating the National Cancer Institute-Working Group 1996 guidelines. Blood. 2008;111(12):5446–5456. - PMC - PubMed
-
- Bahlo J. The International Prognostic Index For Patients With Chronic Lymphocytic Leukaemia (CLL-IPI) ICML; Lugano: 2015. Available from: http://onlinelibrary.wiley.com/doi/10.1002/hon.2227/full. - DOI - PubMed
Publication types
LinkOut - more resources
Full Text Sources
Other Literature Sources